GPC Biotech’s Satraplatin Fails To Meet Survival Endpoint In SPARC Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Next-generation oral platinum chemotherapy remains a Phase II asset worth partnering, CEO Seizinger maintains.